Clinical Trials Logo

Tumors clinical trials

View clinical trials related to Tumors.

Filter by:

NCT ID: NCT02275910 Completed - Tumors Clinical Trials

Phase 1 Study of E7090 in Subjects With Solid Tumor

Start date: October 28, 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.

NCT ID: NCT02182206 Completed - Tumors Clinical Trials

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Start date: June 2003
Phase: Phase 1
Study type: Interventional

Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))

NCT ID: NCT02182128 Completed - Tumors Clinical Trials

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Start date: June 2006
Phase: Phase 1
Study type: Interventional

Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers, and efficacy of BIBF 1120.

NCT ID: NCT02110355 Completed - Cancer Clinical Trials

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Start date: December 19, 2014
Phase: Phase 1
Study type: Interventional

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

NCT ID: NCT01985555 Completed - Tumors Clinical Trials

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

HMPL-504
Start date: May 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose) or RPTD(recommended Phase 2 dose).

NCT ID: NCT01962103 Completed - Cancer Clinical Trials

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Start date: December 4, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.

NCT ID: NCT01837667 Completed - Cancer Clinical Trials

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Start date: February 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of cancer (chemotherapeutic agents). Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of the trade names for docetaxel is Taxotere®. The study is in 2 parts. Part 1: Patients will receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and docetaxel. This is the first study where LB-100 for Injection will be used in humans.

NCT ID: NCT01723020 Completed - Cancer Clinical Trials

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Start date: December 27, 2012
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

NCT ID: NCT01609556 Completed - Tumors Clinical Trials

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

IMGN853-0401
Start date: June 28, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.

NCT ID: NCT01448759 Completed - Tumors Clinical Trials

Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

ALCOOTAX
Start date: October 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.